Azitra (AZTR) Current Deferred Revenue (2022 - 2023)

Azitra's (AZTR) quarterly Current Deferred Revenue came in at $310700.0 in Q2 2023, up 99.17% on a QoQ basis from $156000.0 in Q4 2022.

Azitra (AZTR) Current Deferred Revenue (2022 - 2023) Analysis & Trends

Azitra (AZTR) has 2 years of Current Deferred Revenue data on file, last reported at $310700.0 in Q2 2023.

Quarterly Current Deferred Revenue changed N/A year-over-year to $310700.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $310700.0 (changed N/A YoY) and the FY2022 annual result came in at $156000.0, changed N/A from the prior year.
Current Deferred Revenue advanced to $310700.0 in Q2 2023, from $156000.0 in the prior quarter.
In the past five years, Current Deferred Revenue ranged from a high of $310700.0 in Q2 2023 to a low of $156000.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Azitra	2.53 Mn	2.53 Mn	-

Download Data

Date	Value
Jun 30, 2023	310,700.00
Dec 31, 2022	156,000.00